- Sartorius reported stable nine-month results for 2024, with sales revenue slightly down by 2% but order intake up 6.6%.
- The underlying EBITDA margin was robust at 27.7%, driven by an efficiency program.
Thu Oct 17 06:09:59 -0000 2024 UTC– Sartorius Group’s nine-month results show stable sales revenue, increasing orders, and profitability in line with expectations. The outlook for 2024 remains positive, with expected stable sales and profitability. The company is well-positioned for future growth in life sciences and biopharmaceutical markets.
The company’s CEO is positive about future growth in the life science and biopharmaceutical markets. Financial indicators and divisional performance are detailed, with confirmed outlook for 2024. The company emphasizes its position in providing innovative technologies and solutions in the industry
Weak Demand in China
Bioprocess Solutions sales remained steady, while Lab Products & Services faced challenges in weak markets, especially China.
Despite a decrease in EBITDA and net profit, Sartorius maintained a strong balance sheet and increased cash flow by 13%.